title: [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
abstract: When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor.Pregabalin is one of the first-line treatments for painful diabetic peripheral neuropathy in many countries, and we have administered it to relieve the neurotoxicity associated with adverse effects of VCR in a DLBCL patient treated with the R-CHOP regimen.A 49-year-old man with kidney DLBCL had surgery performed.Afterward, the R-CHOP regimen was introduced.In order to relieve the neurotoxicity of VCR, pregabalin was used from day 8 in the second course.The severity of sensory neurotoxicity after the administration of pregabalin was improved from CTCAE(v4.0)grade 3 to grade 1.Therefore, there is a possibility that VCR-induced neurotoxicity is relieved by pregabalin.Further trials are needed to confirm the value of pregabalin.
authors.affiliation: Department of Pharmacy, National Hospital Organization Kure Medical Center and Chugoku Cancer Center.
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Nakashima
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Kiba
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Akiko
authors.initials: A
authors.lastname: Kimura
authors.forename: Miki
authors.initials: M
authors.lastname: Kido
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Okikawa
authors.forename: Takuo
authors.initials: T
authors.lastname: Ito
authors.forename: Akihisa
authors.initials: A
authors.lastname: Saito
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hosokawa
authors.forename: Hiromi
authors.initials: H
authors.lastname: Shintani
authors.forename: Yuko
authors.initials: Y
authors.lastname: Okada
authors.forename: Takako
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Taniyama
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kozawa
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Niimi
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000601:surgery; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010523:Peripheral Nervous System Diseases / Q000517:prevention & control*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D000069583:Pregabalin; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone